Hunan Fangsheng Pharmaceutical Co., Ltd.
603998.SS
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.67B
Close$
$24.02
132% upside
Current Fair Value
132% upsideUndervalued by 132% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.67 Billion |
|---|---|
| Enterprise Value | $4.79 Billion |
| Dividend Yield | $0.45 (4.70%) |
| Earnings per Share | $0.7 |
| Beta | 0.28 |
| Outstanding Shares | 439,081,360 |
Return
| Return on Equity | 18.84% |
|---|---|
| Return on Assets | 10.83% |
| Return on Invested Capital | 20.78% |
Valuation & Multiples
| P/E Ratio | 14.04 |
|---|---|
| PEG | 40.21 |
| Price to Sales | 2.59 |
| Price to Book Ratio | 2.59 |
| Enterprise Value to Revenue | 2.56 |
| Enterprise Value to EBIT | 11.75 |
| Enterprise Value to Net Income | 14 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.2 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 29, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$494.97 M
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$494.88 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Hunan Fangsheng Pharmaceutical Co., Ltd.
1,868 employees
CEO: Xiaoli Zhou Operating within China, Hunan Fangsheng Pharmaceutical Co., Ltd. is engaged in the complete spectrum of pharmaceutical activities, from research and development to manufacturing and sales. Its diverse product line encompasses tablets, ca...